Product Guide

Material for food, food supplement and beverage

Material for food, food supplement, and beverage/Patent Obtained/MP Marine Placenta®

Evidence

Anti-aging test

Double blind trials with adult monitors from the general population were conducted to validate the anti-aging effects of Marine Placenta(Product code:MP100) (hereinafter "Marine Placenta").

Testing Agency FCG Research Institute Ltd. (Koto-ku, Tokyo)

Intake Period 8 weeks (mid of January to mid of March 2006)

Method of consumption Dosage ; 4 tablets/day (1 tablet: 250mg) - Marine Placenta Intake: 490mg/day
Samples ;
1)Tablets containing Marine Placenta
2)Placebo tablets not containing Marine Placenta

Monitors A group of 20 healthy females aged 40±2 years with dry skin type and suffering from dry skin or sensitivity to cold were assigned into a group receiving Marine Placenta (10 members) and a group receiving placebo (10 members).

Test Result 1) Change in wrinkle factor The wrinkle factor is expressed in a 5-level scale, with lower numbers indicating less prominent wrinkles. Class 1 "No visible wrinkles" - less than 3.0, Class 2, "Faint visible wrinkles" - 3.0 to 4.5, Class 3 "Visible wrinkles" - 4.5 to 6.0, Class 4 "Wrinkles clearly visible" - 6.0 to 7.5,Class 5 "Clearly visible deep wrinkles" - 7.5 and up. There are cases of improvement relating to improvement in the elasticity of dermal section.

In the group taking Marine Placenta, wrinkles tended to improve over the course of treatment. At the 8-week point, the wrinkle factor had decreased to approximately one or less. The average wrinkle factor at the start point of the test was 4.9, corresponding to Class 3 wrinkles. After the treatment, the factor had dropped to 4.1, corresponding to Class 2. Thus, the treatment caused decrease of the wrinkle factor's level, indicating that a wrinkle improvement effect can be expected from Marine Placenta.
The followings are examples of improvement in wrinkles when Marine Placenta is taken.

2) Change in peripheral blood circulation function Peripheral blood circulatory function falls with age. Higher figures for this function indicate good health.

In the group taking Marine Placenta over 8 weeks, this score increased. In the control group, the score fell from start point. Peripheral blood circulation function tends to worsen when temperatures go down. Given that the trial was begun in January, in winter, and that the coldest point was 4 weeks after the beginning of the trial, the fact that there was improvement in the score in the group taking the Marine Placenta and not in the placebo group indicates that improvements in peripheral blood circulation function can be expected from consumption of Marine Placenta.

3) Changes in IGF-1 (aging marker). Levels of IGF-1 (also known as somatomedin C) tend to fall with age, hence the increases in IGF-1 levels observed here mean that an anti-aging effect is at work.

In the group taking Marine Placenta, IGF-1 level had increased at the 4-week point, however the level fell in the placebo group. With continued intake of Marine Placenta, the IGF-1 level increased further.
The above results show that in the group taking Marine Placenta an increase in IGF-1 level was seen, and it seems possible to expect that Marine Placenta has an anti-aging effect.

4) Evaluation by monitors The monitors, who did not know which samples they had taken, carried out a self-reported survey on their physical condition and skin condition. These are the results.

Skin Condition Questionnaire

In the group taking Marine Placenta, a overall improvement was seen in all areas. Even after the treatment was stopped, further improvement was seen over the following 2 weeks. Even though skin renews itself in a 28-day period, no deterioration in skin condition was seen directly after the treatment was stopped, and it seems that an effect from the Marine Placenta treatment was still evident 2 weeks after the end of the treatment.

Health/body condition questionnaire

Upon comparing all areas under consideration in the group that took Marine Placenta at the 8-week point and 2 weeks post-trial point, significant differences were seen in sensitivity to cold, tendency to tiredness, and appetite, with a hazard ratio of 1% or lower, and significant differences were seen in joint/hip pain, stiff shoulder, headaches, quality of sleep, sleep, and menstrual irregularities with a hazard ratio of 5% or under. Thus, the group that had not taken Marine Placenta for 2 weeks clearly felt all the areas under consideration in the trial had worsened. Regarding the improvements in the group at the 8-week point, the findings of the questionnaire are further supported by the increase in IGF-1 level and blood circulation function score.

Summary In the group taking Marine Placenta, the monitors were aware of an overall improvement in skin condition and physical condition. Additionally, the data for the wrinkle factor decrease and increase in peripheral blood circulation function score, as well as that for the increase in IGF-1, indicates that an overall anti-aging effect can be expected from Marine Placenta.

Survey on the effectiveness
against menopause symptoms

Trials on the effectiveness of MP Marine Placenta(Product code:MP100) (hereinafter "Marine Placenta") against menopause symptoms were conducted with adult monitors from the general population.

Testing Agency Medical Intelligence Co.,Ltd. (Chiyoda-ku, Tokyo)

Intake Period 8 weeks (end of January to end of March 2008)

Method of consumption Dosage ; 4 tablets/day (1 tablet: 250mg) - Marine Placenta Intake: 490mg/day

Monitors Ten women aged 40-60 years old, who have passed at least 1 year after menopause and who show indefinite symtoms (such as insomnia, hot flushes, palpitations, fatigue, joint pain and irritability).

Test Result 1) Changes in estradiol (E2), follicle-stimulating hormone (FSH), neutral fat, total cholesterol. The following are the percentages of monitors who showed a tendency toward improvement for each of the items evaluated.

2) Changes in estradiol (E2), follicle-stimulating hormone (FSH), and subjective symptom improvement rate

Summary The results of this trial of the effectiveness of Marine Placenta suggest that over the course of an approximately 2-month trial, Marine Placenta promoted improvement of hormone balance in postmenopausal women complaining so-called menopausal symptoms, and improvement of alleviated various symptoms associated with menopause accordingly.

Survey on the Promotion of Hair Growth

Marine Placenta(Product code:MP100) (hereinafter “Marine Placenta”) was orally administered to C57BL/6 mice, and the changes in skin color and skin morphology was observed to evaluate the test substance’s effect on the promotion of hair growth.

Testing Agency Dalian Medical University , China-Japan Cooperative Scientific and Medical Institute (Dalian, China)

Intake Period 25 days (December 3 to December 28, 2009)

Test Result Changes in skin color
The color of the hair loss area on the back of each mouse was observed and recorded every day, divided into the following three growth phases, and photographed.

The number of days which took for the skin color to turn gray after becoming black for the group taking Marine Placenta was clearly longer than the control group, and the difference was statistically significant (p<0.01).

Summary In the group taking Marine Placenta, the growth phase of hair growth was prolonged, and the cessation and rest phases were delayed.
Additionally, the data for increase in duration of glossy black hair compared to the control group indicates that an overall hair growth promoting effect can be expected from Marine Placenta.

Cell Activation Test using Fibroblasts

The cell activating effects of fibroblasts, using normal human dermal fibroblasts, was evaluated for Marine Placenta(Product code:MP100) (hereinafter “Marine Placenta”).

Testing Agency Nikoderm Research Inc. (Chuo-ku, Osaka)

Test Period January 10 to February 16, 2012

Test Method Normal human dermal fibroblasts were incubated for 48 hours in a medium that does not contain Marine Placenta (Control), and a medium that contains Marine Placenta. The mitochondrial metabolic activities of the cultured cells were evaluated using the amount of reduction in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test sample as the index. The MTT reduction amount in the Control cells was expressed as a percentage, and the difference of the two mediums was evaluated using Student's t-test.

Test Result

Summary A significant cell activating effect of more than 10% over the Control was observed with Marine Placenta.

Type Ⅰ Collagen Production Test using Fibroblast

The promotion of type Ⅰ collagen production using normal human dermal fibroblasts was evaluated for Marine Placenta(Product code:MP100) (hereinafter “Marine Placenta”).

Testing Agency Nikoderm Research Inc. (Chuo-ku, Osaka)

Test Period January 10 to February 16, 2012

Test Method Normal human dermal fibroblasts were incubated for 24 hours in a medium that does not contain Marine Placenta (Control), and a medium that contains Marine Placenta. The amount of type Ⅰ collagen in the conditioned medium was quantified using the ELISA method. Additionally, the cells were dissolved with Triton X-100 solution, and the amount of protein was quantified. The result was expressed as the amount of collagen produced per amount of protein units, which is calculated by dividing the amount of collagen in the medium by the protein amount of all cells, and the difference of the two mediums was evaluated using Student’s t-test.

Test Result

Summary A significant collagen production effect was observed with Marine Placenta.

Antioxidant action

We tested the antioxidant action of Marine Placenta(Product code:MP100) (hereinafter “Marine Placenta”) on singlet oxygen, a species of reactive oxygen.

Testing AgencyShowa University, Medical Dept. (Shinagawa-ku, Tokyo)

Test periodDecember 19, 2011 to November 2, 2012

Test MethodElectron spin resonance apparatus (ESR) was used to measure the ESR spectrum of a control substance and that of the control mixed with Marine Placenta after artificially inducing both substances to generate singlet oxygen.
The ability of the substance containing Marine Placenta to scavenge singlet oxygen was tested, with the peak intensity of the ESR spectrum of the control set at 100.

Test Result

Summary The results showed that Marine Placenta had an antioxidant action against singlet oxygen, a species of reactive oxygen, and moreover that this action increased with increasing doses of Marine Placenta. Furthermore, it was found that Marine Placenta had an antioxidant action against hydroxyl radical and nitric monoxide, both species of reactive oxygen, and moreover that this action increased with increasing doses of Marine Placenta. (Please contact us for details of the tests with hydroxyl radical and nitric monoxide.)

ORAC Value The ORAC value (Oxygen Radical Absorbance Capacity) is an index that measures antioxidant power. The Total - ORAC value of Marine Placenta was found to be 220μmol TE/g.

Marine Placenta is a registered trademark of Nippon Barrier Free Co., Ltd.

Marine Placenta is a registered trademark for Salmon Ovary Membrane Extract.
Moreover, the names of services and products handled by Nippon Barrier Free Co., Ltd. are trademarks or registered trademarks of Nippon Barrier Free Co., Ltd.
All expressions (such as text, illustrations, and images) within this site are protected by copyright law.
Copying, replicating, or broadcasting any of the content without permission will be subject to punishment by copyright law and other intellectual property laws.

∗ Please follow the related laws and regulations when displaying or advertising health foods and cosmetics that contain our products.

In the case of linking to this site, please contact us in advance.

Page Top